Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression

Motoi Kanagawa, Chih Chieh Yu, Chiyomi Ito, So Ichiro Fukada, Masako Hozoji-Inada, Tomoko Chiyo, Atsushi Kuga, Megumi Matsuo, Kanoko Sato, Masahiko Yamaguchi, Takahito Ito, Yoshihisa Ohtsuka, Yuki Katanosaka, Yuko Miyagoe-Suzuki, Keiji Naruse, Kazuhiro Kobayashi, Takashi Okada, Shin'ichi Takeda, Tatsushi Toda

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

A group of muscular dystrophies, dystroglycanopathy is caused by abnormalities in post-translational modifications of dystroglycan (DG). To understand better the pathophysiological roles of DG modification and to establish effective clinical treatment for dystroglycanopathy, we here generated two distinct conditional knock-out (cKO) mice for fukutin, the first dystroglycanopathy gene identified for Fukuyama congenital muscular dystrophy. The first dystroglycanopathy model-myofiber-selective fukutin-cKO [muscle creatine kinase (MCK)-fukutin-cKO] mice-showed mild muscular dystrophy. Forced exercise experiments in presymptomatic MCK-fukutin-cKO mice revealed that myofiber membrane fragility triggered disease manifestation. The second dystroglycanopathy model-muscle precursor cell (MPC)-selective cKO (Myf5-fukutin-cKO) mice-exhibited more severe phenotypes of muscular dystrophy. Using an isolated MPC culture system, we demonstrated, for the first time, that defects in the fukutin-dependent modification of DG lead to impairment of MPC proliferation, differentiation and muscle regeneration. These results suggest that impaired MPC viability contributes to the pathology of dystroglycanopathy. Since our data suggested that frequent cycles of myofiber degeneration/regeneration accelerate substantial and/or functional loss of MPC, we expected that protection from disease-triggering myofiber degeneration provides therapeutic effects even in mouse models with MPC defects; therefore, we restored fukutin expression in myofibers. Adeno-associated virus (AAV)-mediated rescue of fukutin expression that was limited in myofibers successfully ameliorated the severe pathology even after disease progression. In addition, compared with other gene therapy studies, considerably low AAV titers were associated with therapeutic effects. Together, our findings indicated that fukutin-deficient dystroglycanopathy is a regeneration-defective disorder, and gene therapy is a feasible treatment for the wide range of dystroglycanopathy even after disease progression.

Original languageEnglish
Article numberddt157
JournalHuman Molecular Genetics
Volume22
Issue number15
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Muscular Dystrophies
Myoblasts
Glycosylation
Dystroglycans
Knockout Mice
Phenotype
Gene Expression
Muscles
MM Form Creatine Kinase
Regeneration
Dependovirus
Therapeutic Uses
Genetic Therapy
Disease Progression
Walker-Warburg Syndrome
Pathology
Cytoprotection
Post Translational Protein Processing
Viral Load
Cell Differentiation

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology
  • Medicine(all)

Cite this

Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. / Kanagawa, Motoi; Yu, Chih Chieh; Ito, Chiyomi; Fukada, So Ichiro; Hozoji-Inada, Masako; Chiyo, Tomoko; Kuga, Atsushi; Matsuo, Megumi; Sato, Kanoko; Yamaguchi, Masahiko; Ito, Takahito; Ohtsuka, Yoshihisa; Katanosaka, Yuki; Miyagoe-Suzuki, Yuko; Naruse, Keiji; Kobayashi, Kazuhiro; Okada, Takashi; Takeda, Shin'ichi; Toda, Tatsushi.

In: Human Molecular Genetics, Vol. 22, No. 15, ddt157, 08.2013.

Research output: Contribution to journalArticle

Kanagawa, M, Yu, CC, Ito, C, Fukada, SI, Hozoji-Inada, M, Chiyo, T, Kuga, A, Matsuo, M, Sato, K, Yamaguchi, M, Ito, T, Ohtsuka, Y, Katanosaka, Y, Miyagoe-Suzuki, Y, Naruse, K, Kobayashi, K, Okada, T, Takeda, S & Toda, T 2013, 'Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression', Human Molecular Genetics, vol. 22, no. 15, ddt157. https://doi.org/10.1093/hmg/ddt157
Kanagawa, Motoi ; Yu, Chih Chieh ; Ito, Chiyomi ; Fukada, So Ichiro ; Hozoji-Inada, Masako ; Chiyo, Tomoko ; Kuga, Atsushi ; Matsuo, Megumi ; Sato, Kanoko ; Yamaguchi, Masahiko ; Ito, Takahito ; Ohtsuka, Yoshihisa ; Katanosaka, Yuki ; Miyagoe-Suzuki, Yuko ; Naruse, Keiji ; Kobayashi, Kazuhiro ; Okada, Takashi ; Takeda, Shin'ichi ; Toda, Tatsushi. / Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. In: Human Molecular Genetics. 2013 ; Vol. 22, No. 15.
@article{c6c94e442cc74f4c8e4617455831b7e3,
title = "Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression",
abstract = "A group of muscular dystrophies, dystroglycanopathy is caused by abnormalities in post-translational modifications of dystroglycan (DG). To understand better the pathophysiological roles of DG modification and to establish effective clinical treatment for dystroglycanopathy, we here generated two distinct conditional knock-out (cKO) mice for fukutin, the first dystroglycanopathy gene identified for Fukuyama congenital muscular dystrophy. The first dystroglycanopathy model-myofiber-selective fukutin-cKO [muscle creatine kinase (MCK)-fukutin-cKO] mice-showed mild muscular dystrophy. Forced exercise experiments in presymptomatic MCK-fukutin-cKO mice revealed that myofiber membrane fragility triggered disease manifestation. The second dystroglycanopathy model-muscle precursor cell (MPC)-selective cKO (Myf5-fukutin-cKO) mice-exhibited more severe phenotypes of muscular dystrophy. Using an isolated MPC culture system, we demonstrated, for the first time, that defects in the fukutin-dependent modification of DG lead to impairment of MPC proliferation, differentiation and muscle regeneration. These results suggest that impaired MPC viability contributes to the pathology of dystroglycanopathy. Since our data suggested that frequent cycles of myofiber degeneration/regeneration accelerate substantial and/or functional loss of MPC, we expected that protection from disease-triggering myofiber degeneration provides therapeutic effects even in mouse models with MPC defects; therefore, we restored fukutin expression in myofibers. Adeno-associated virus (AAV)-mediated rescue of fukutin expression that was limited in myofibers successfully ameliorated the severe pathology even after disease progression. In addition, compared with other gene therapy studies, considerably low AAV titers were associated with therapeutic effects. Together, our findings indicated that fukutin-deficient dystroglycanopathy is a regeneration-defective disorder, and gene therapy is a feasible treatment for the wide range of dystroglycanopathy even after disease progression.",
author = "Motoi Kanagawa and Yu, {Chih Chieh} and Chiyomi Ito and Fukada, {So Ichiro} and Masako Hozoji-Inada and Tomoko Chiyo and Atsushi Kuga and Megumi Matsuo and Kanoko Sato and Masahiko Yamaguchi and Takahito Ito and Yoshihisa Ohtsuka and Yuki Katanosaka and Yuko Miyagoe-Suzuki and Keiji Naruse and Kazuhiro Kobayashi and Takashi Okada and Shin'ichi Takeda and Tatsushi Toda",
year = "2013",
month = "8",
doi = "10.1093/hmg/ddt157",
language = "English",
volume = "22",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression

AU - Kanagawa, Motoi

AU - Yu, Chih Chieh

AU - Ito, Chiyomi

AU - Fukada, So Ichiro

AU - Hozoji-Inada, Masako

AU - Chiyo, Tomoko

AU - Kuga, Atsushi

AU - Matsuo, Megumi

AU - Sato, Kanoko

AU - Yamaguchi, Masahiko

AU - Ito, Takahito

AU - Ohtsuka, Yoshihisa

AU - Katanosaka, Yuki

AU - Miyagoe-Suzuki, Yuko

AU - Naruse, Keiji

AU - Kobayashi, Kazuhiro

AU - Okada, Takashi

AU - Takeda, Shin'ichi

AU - Toda, Tatsushi

PY - 2013/8

Y1 - 2013/8

N2 - A group of muscular dystrophies, dystroglycanopathy is caused by abnormalities in post-translational modifications of dystroglycan (DG). To understand better the pathophysiological roles of DG modification and to establish effective clinical treatment for dystroglycanopathy, we here generated two distinct conditional knock-out (cKO) mice for fukutin, the first dystroglycanopathy gene identified for Fukuyama congenital muscular dystrophy. The first dystroglycanopathy model-myofiber-selective fukutin-cKO [muscle creatine kinase (MCK)-fukutin-cKO] mice-showed mild muscular dystrophy. Forced exercise experiments in presymptomatic MCK-fukutin-cKO mice revealed that myofiber membrane fragility triggered disease manifestation. The second dystroglycanopathy model-muscle precursor cell (MPC)-selective cKO (Myf5-fukutin-cKO) mice-exhibited more severe phenotypes of muscular dystrophy. Using an isolated MPC culture system, we demonstrated, for the first time, that defects in the fukutin-dependent modification of DG lead to impairment of MPC proliferation, differentiation and muscle regeneration. These results suggest that impaired MPC viability contributes to the pathology of dystroglycanopathy. Since our data suggested that frequent cycles of myofiber degeneration/regeneration accelerate substantial and/or functional loss of MPC, we expected that protection from disease-triggering myofiber degeneration provides therapeutic effects even in mouse models with MPC defects; therefore, we restored fukutin expression in myofibers. Adeno-associated virus (AAV)-mediated rescue of fukutin expression that was limited in myofibers successfully ameliorated the severe pathology even after disease progression. In addition, compared with other gene therapy studies, considerably low AAV titers were associated with therapeutic effects. Together, our findings indicated that fukutin-deficient dystroglycanopathy is a regeneration-defective disorder, and gene therapy is a feasible treatment for the wide range of dystroglycanopathy even after disease progression.

AB - A group of muscular dystrophies, dystroglycanopathy is caused by abnormalities in post-translational modifications of dystroglycan (DG). To understand better the pathophysiological roles of DG modification and to establish effective clinical treatment for dystroglycanopathy, we here generated two distinct conditional knock-out (cKO) mice for fukutin, the first dystroglycanopathy gene identified for Fukuyama congenital muscular dystrophy. The first dystroglycanopathy model-myofiber-selective fukutin-cKO [muscle creatine kinase (MCK)-fukutin-cKO] mice-showed mild muscular dystrophy. Forced exercise experiments in presymptomatic MCK-fukutin-cKO mice revealed that myofiber membrane fragility triggered disease manifestation. The second dystroglycanopathy model-muscle precursor cell (MPC)-selective cKO (Myf5-fukutin-cKO) mice-exhibited more severe phenotypes of muscular dystrophy. Using an isolated MPC culture system, we demonstrated, for the first time, that defects in the fukutin-dependent modification of DG lead to impairment of MPC proliferation, differentiation and muscle regeneration. These results suggest that impaired MPC viability contributes to the pathology of dystroglycanopathy. Since our data suggested that frequent cycles of myofiber degeneration/regeneration accelerate substantial and/or functional loss of MPC, we expected that protection from disease-triggering myofiber degeneration provides therapeutic effects even in mouse models with MPC defects; therefore, we restored fukutin expression in myofibers. Adeno-associated virus (AAV)-mediated rescue of fukutin expression that was limited in myofibers successfully ameliorated the severe pathology even after disease progression. In addition, compared with other gene therapy studies, considerably low AAV titers were associated with therapeutic effects. Together, our findings indicated that fukutin-deficient dystroglycanopathy is a regeneration-defective disorder, and gene therapy is a feasible treatment for the wide range of dystroglycanopathy even after disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84880256175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880256175&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddt157

DO - 10.1093/hmg/ddt157

M3 - Article

C2 - 23562821

AN - SCOPUS:84880256175

VL - 22

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 15

M1 - ddt157

ER -